期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 28, 期 2, 页码 152-160出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000255
关键词
biologics; cytokines; glycoprotein 130; interleukin-6; therapy
类别
资金
- Arthritis Research UK
- Versus Arthritis [20305, 20770] Funding Source: researchfish
Purpose of reviewBiological drugs that target the inflammatory cytokine interleukin-6 (IL-6) are increasingly considered as therapies for chronic disease and cancer. The purpose of this review is to place the biology of IL-6 in context. Here, we provide information on the biology behind IL-6 and consider mechanisms that are relevant to the application of IL-6 targeted therapies.Recent findingsThe clinical blockade of IL-6 activity with tocilizumab has fuelled considerable interest in the biology behind this inflammatory cytokine. Although IL-6 impacts both innate and adaptive immunity, and the control of tissue homeostasis, the signalling mechanisms that control IL-6 responsiveness are complex. Several alternative IL-6-directed interventions with unique modes of action are now approaching the clinic. However, various questions still remain about how and when to block IL-6. Owing to the complexity of IL-6 biology, this is not trivial. In this review, we introduce the immunobiology of IL-6 and explore the different therapeutic strategies in development that inhibit IL-6 activity.SummaryVarious inhibitors of IL-6 bioactivity are now in development of routine clinical practice. The key is to understand how best to apply these drugs. This review provides useful insight into the workings of IL-6 in health and disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据